No specific target. There will be an early pop today and if it starts to fade I'll punch my ticket. I'm fortunate to have bought long ago in the single digits so I'm not going quibble on the exit price. I do admit I think this company will eventually be acquired so I'm concerned about missing that but I'm still inclined to take the money and run.
...a few warnings signs:
1. Dependence on single customer: "Revenues related to our delivery of all products sold to Rabobank globally exceeded 30% of the first quarter's revenue."
2. Forward guidance: "We expect that comparisons of 2015 results to the prior year will be stronger in the first half of this year than in the second half."
No, I am not short and have been long for ~ 5 years, but I will be looking for the exit door over the next few days.
Halozyme Therapeutics (HALO) Bullish Stance Reiterated at BMO Capital Amid Positive AACR Update
7:51 AM ET, 04/20/2015 - StreetInsider
BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $26 price target on Halozyme Therapeutics (NASDAQ: HALO) after the American Association of Cancer Research meeting where, over the weekend, Halozyme PEGPH20 investigator, Dr. Sunil Hingorani discussed the targeting of hyaluronan (HA) in pancreatic cancer, noting that PEGPH20 combined with chemotherapy results in permanent favorable architectural changes after stoppage of PEGPH20.
Birchenough commented, "We maintain our Outperform rating on HALO following this weekend's AACR presentation and on prospects for PEGPH20 in pancreatic CA and other cancers with high HA expression. With impressive response rate and PFS data already established, we believe that enhanced biologic understanding of PEGPH20 action further increases confidence in prospects for success in pancreatic Ca. Durable benefit following early PEGPH20 termination and lasting effects on tumor vasculature could inform new dosing strategies to optimize therapeutic index across tumor types and realize the broad potential of PEGPH20 as a platform to enhance chemotherapy efficacy. We continue to see PEGPH20 as an undervalued asset, in the context of a HALO valuation that can be supported by partnered PH20 programs like HERCEPTIN SC and MABTHERA SC."
Actually your statement, "This move by management to offer to itself a special preferred stock with super voting rights, makes taking over board of VDSI virtually impossible" is incorrect, and should be amended to read, "This move by management to offer to itself a special preferred stock with super voting rights, makes taking over board of VDSI virtually impossible WITHOUT THE CONSENT OF THE BOARD". Everything is for sale at the right price. The CEO is 71 yo, owns 25% of the float, and should be ready to cash in his chips.
I rarely post but since there seems to be a new idiot on the board I felt the need to step up. Many of the company's officers exercised their options in March and, AS IS STANDARD OPERATING PROCDURE, sold a FRACTION of them to cover their tax liability, while holding on to the remainder.
So, if they knew margins would be under pressure they should not have said anything and left themselves open to a lawsuit?
From Dec 22, 2014 SEC 8K filing. If this doesn't make your blood boil, nothing will:
On December 19, 2014, Walter Energy, Inc. (the “Company”) entered into award agreements (each, an “Award Agreement”) with three of the Company’s current named executive officers, Walter J. Scheller, III, William G. Harvey and Earl H. Doppelt. The terms of the Award Agreements with such executive officers provide that they will receive a cash award (the “Award”), to be paid by the Company on the effective date of the Award Agreement, equal to a multiple of such executive officer’s current annual base salary. Pursuant to their respective Award Agreements, Mr. Scheller received an Award of $2,400,000 (or approximately 2.9x his current base salary), Mr. Harvey received an Award of $1,300,000 (or approximately 2.6x his current base salary) and Mr. Doppelt received an Award of $1,100,000 (or approximately 2.4x his current base salary). These awards are intended to recognize excellent individual performance and to retain the services of the executives for three full years in a challenging environment. Under the terms of each such executive officer’s Award Agreement, the executive officer will be required to repay the full gross amount of the Award to the Company if such executive officer’s employment with the Company is terminated by the executive officer without good reason (as defined in the Award Agreement), which would include a retirement by the executive officer without good reason, or by the Company for cause (as defined in the Award Agreement) prior to the third anniversary of the effective date of the Award Agreement.
Yes, the bond holders are savvy investors like you. In a financially distressed company they'd rather have common stock (at the bottom of the food chain) rather than senior notes. Dream on.
Notes could have been selling at 10 cents on the dollar or maybe there was no bid at all. They probably thought the chance of Walter being around in 2021 and getting the full value of the notes was remote and by getting the common shares they gained some liquidity and could sell them immediately and at least recover some $$$ of their investment. These shares hitting the market could have been responsible for the big decline the past 2 days.
Keep your pants on. It's a rumor, but a sensible one. With the major stockholder over 70 yo I've long maintained he'd be looking to cash in his chips sooner or later. However I believe the price you mentioned is too low.
August, 2013, some penny stock rag was pumping it. Friday's action might have been some front running before another similar "recommendation" comes out. Best case scenario would be a buy out, because with its high level of debt it can't survive much longer as an independent company. I've been an "investor" for years and still have some shares, but mentally I've written it off as a total loss.